Monitor for execution of the 144 sale; continued distribution by this VC holder could pressure the stock near-term. TYRA's strong institutional support and 90% analyst buy rating provide a cushion, but the selling pattern warrants caution in the coming days to weeks.
TYRA drugs
TYRA drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $32.11entry
- T+1 · 5mo ago −0.53%α −1.31% · $31.94
- T+5 · 4mo ago −3.89%α −5.28% · $30.86
- T+20 · 4mo ago −4.61%α −4.33% · $30.63
- T+60 · 8w ago −20.37%α −24.75% · $25.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nextech VI Oncology SCSP, a significant VC shareholder, filed a Form 144 to sell 308,379 shares (~$9.5M) after already selling ~129k shares (~$4M) in the prior week. This signals near-term profit-taking and creates overhang, potentially weighing on TYRA shares despite strong fundamentals.
Key Facts
- Nextech VI Oncology SCSP plans to sell 308,379 common shares, valued at ~$9.5M.
- Same entity sold 128,949 shares (~$4.0M) in the week prior (June 1, 23-25, 2026).
- Proposed sale is ~0.58% of TYRA's $1.8B market cap; combined recent+proposed is ~0.75%.
- Shares were acquired in a private placement on Sep 17, 2021, now being steadily sold.
Financial Impact
~$9.5M proposed sale, combined recent and proposed ~$13.6M
Risk Factors
- Further selling by Nextech VI Oncology SCSP beyond the proposed 308k shares
- Negative signal from a major early investor reducing its stake
- Potential short-term price dislocation from large block sale
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-045813 |
| Document: 0001628280-26-045813-index.html | 0001628280-26-045813 |
| Document: 0001628280-26-045813.txt | 0001628280-26-045813 |
Track record
13 reports on TYRA
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +17.37% at T+60 after the Aug 4, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $21.00 Now $19.74 −6.00% settles Nov 17
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
- Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
- Sep 14, 20269w ago S-3ASR Neutral 3/10 Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
- Aug 4, 202614w ago 424B5 Bearish 6/10 Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Viewing Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
- May 13, 202626w ago 8-K Mixed 5/10 Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
- Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers